Flatt, Peter R.

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 1,868

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity

Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 125

A novel glucagon-like peptide-1 (GLP-1)/Glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice

Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 123

An update on peptide-based therapies for type 2 diabetes and obesity

Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 111

Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents

Green, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 111

Plant-based Diets and Phytochemicals in the Management of Diabetes Mellitus and Prevention of its Complications: A Review

Ansari, P., Khan, J. T., Choudhary, S., Reberio, A. D., Kumar, S., Seidel, V., Abdel-Wahab, Y. H. A., & Flatt, P. R. (2024) · Nutrients

Natural Antidiabetic Agents StudiesNutritional Studies and Diet

Cited by 89

Dorothy Hodgkin Lecture 2008 Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity–diabetes?

Flatt, P. R. (2008) · Diabetic Medicine

Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

Cited by 68

Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic β-cell glucose metabolism and insulin secretion

Patterson, S., Flatt, P. R., Brennan, L., Newsholme, P., & McClenaghan, N. H. (2006) · Journal of Endocrinology

Pancreatic function and diabetesFolate and B Vitamins Research

Cited by 63

A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores

Martin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 53

Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice

Green, B. D., Lavery, K. S., Irwin, N., O’Harte, F. P. M., Harriott, P., Greer, B., Bailey, C. J., & Flatt, P. R. (2006) · The Journal of Pharmacology and Experimental Therapeutics

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 49

Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice

Lennox, R., Flatt, P. R., & Gault, V. A. (2014) · Peptides

Diabetes Treatment and ManagementNeurogenesis and neuroplasticity mechanisms

Cited by 47

Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes

Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity

Pancreatic function and diabetesNeuropeptides and Animal Physiology

Cited by 42

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes

Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 41

Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline

Irwin, N., Flatt, P. R., Patterson, S., & Green, B. D. (2010) · European Journal of Pharmacology

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 38

Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes

Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides

Adipokines, Inflammation, and Metabolic DiseasesRegulation of Appetite and Obesity

Cited by 27

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 25